Ascites and epithelial ovarian cancers: A reappraisal with respect to different aspects

International Journal of Gynecological Cancer

Volumn 17, Issue 1, 2007, Pages 68-75

  Ayhan, A ^a   Gultekin, M ^a   Taskiran, C ^a   Dursun, P ^a   Firat, P ^a   Bozdag, G ^a   Celik, N Y ^a   Yuce, K ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Ascites; Cytology; Epithelial ovarian cancer; Survival; Volume

Indexed keywords

CARBOPLATIN; CISPLATIN;

ADULT; ARTICLE; ASCITES; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHI SQUARE TEST; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLOGY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; METASTASIS; OMENTUM; OVARY CANCER; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANK SUM TEST; RETROPERITONEAL CANCER; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; EPITHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 33846815431     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00777.x     Document Type: Article

References (32)

1. Sorbe B, Frankendal B. Prognostic importance of ascites in ovarian carcinoma. Acta Obstet Gynecol Scand 1983;62:415-8.
2. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 1971;37:1-9.
3. Day TG Jr, Smith JP. Diagnosis and staging of ovarian carcinoma. Semin Oncol 1975;2:217-22.
4. Review of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol 1979;135:984-93.
5. Smith WG. Surgical treatment of epithelial ovarian carcinoma. Clin Obstet Gynecol 1979;22:939-56.
6. Makar AP, Baekelandt M, Trope CG, Kristensen GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995;56:175-80.
7. Berek JS, Hacker NF, Lagasse LD, Poth T, Resnick B, Nieberg RK. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status. Obstet Gynecol 1984;64:207-12.
8. Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990;75:263-73.
9. Puls LE, Duniho T, Hunter JE, Kryscio R, Blackhurst D, Gallion H. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol 1996;61:109-12.
10. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994;10:31-46.
11. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer 2001;85:944-52.
12. Chi DS, Liao JB, Leon LF et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001;82:532-7.
13. Heintz AP, Van Oosterom AT, Trimbos JB, Schaberg A, Van der Velde EA, Nooy M. The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. Gynecol Oncol 1988;30:347-58.
14. Van Houwelingen JC, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Neijt JP. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol 1989;7:769-73.
15. Omura GA, Brady MF, Homesley HD et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:1138-50.
16. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985;65:264-70.
17. Einhorn N, Nilsson B, Sjovall K. Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population. Cancer 1985;55:2019-25.
18. Ansell SM, Rapoport BL, Falkson G, Raats JI, Moeken CM. Survival determinants in patients with advanced ovarian cancer. Gynecol Oncol 1993;50:215-20.
19. Hirabayashi K, Graham J. Genesis of ascites in ovarian cancer. Am J Obstet Gynecol 1970;106:492-7.
20. Feldman GB, Knapp RC, Order SE, Hellman S. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 1972;32:1663-6.
21. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol 1998;25:326-34.
22. Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 2003;21:3488-94.
23. Randall TC, Rubin SC. Surgical management of ovarian cancer. Semin Surg Oncol 1999;17:173-80.
24. Flam F, Einhorn N, Sjovall K. Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1988;27:53-7.
25. Granberg S, Noren H, Friberg LG. Ovarian cancer stages I and II: predictions and 5-year survival in two decades. Gynecol Oncol 1989;35:204-8.
26. Zuckerman E, Lanir A, Sabo E et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999;94:1613-8.
27. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-62.
28. Yoshimura S, Scully RE, Bell DA, Taft PD. Correlation of ascitic fluid cytology with histologic findings before and after treatment of ovarian cancer. Am J Obstet Gynecol 1984;148:716-21.
29. Von Gruenigen VE, Frasure HE, Reidy AM, Gil KM. Clinical disease course during the last year in ovarian cancer. Gynecol Oncol 2003;90:619-24.
30. Belfort MA, Stevens PJ, DeHaek K, Soeters R, Krige JE. A new approach to the management of malignant ascites; a permanently implanted abdominal drain. Eur J Surg Oncol 1990;16:47-53.
31. Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR Jr, Skubitz AP. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 2004;93:170-81.
32. Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 1990;86:851-5.